And then we’re seeing that even quickly or more quicker accelerate in the first eight weeks of Q1. And that’s why we’re saying we’re encouraged with those trends. And that’s why we think probably by midyear that the inventory will have been — would be pretty much drawn down at those clinic levels. We would expect the reorder rates to continue to accelerate as we move forward through the first quarter and the second quarter of this year. So, we have good visibility, but you mentioned also prescriptions. I mean, we don’t get that data, obviously, like I mentioned earlier on the call, this is a buy and build sort of market in a way. So, we look at orders and yes, so that — I think that was the last part of your question.
Oren Livnat: I mean, someone knows how many boxes or vials are still sitting at the wholesaler per inventory management agreement, I would assume, right?
Chris Posner: Of course.
Oren Livnat: Okay. But we won’t tell us that?
Chris Posner: Well, no. I mean, Oren, what’s really important is that we said by mid-2023 we expect what I call a more demand-based trajectory, meaning demand will drive shipments from the wholesalers. They’ll converge. Right now we have to work down the inventory of Fresenius. But I view the Fresenius thing as a real positive. They took this very atypical approach because they believe in the product and believe in helping their patients. And they really want to make this available across their network. And they invested significant time and dollars in this. And this is — that was in Q3, and now we’re seeing that drive thru in Q4 and we’re seeing that accelerate in the first part of Q1.
Oren Livnat: Also, on those 21,000 vials that were ordered this quarter on top of inventory being worked through. Can you characterize who ordered those? I think you said there were reorders from Fresenius centers. Can you give us any mix on where those went?
Chris Posner: Yes. I would say the 20,000 or 21,000, obviously, it’s a combination reorders for Fresenius and also we have two other customer segments, right,? We have DaVita and then we have the mid-size and independents. So I would say Q4 is probably closer to 50-50.
Oren Livnat: And just lastly, if I may, on the post TDAPA bundling decision, I understand, you’re still hoping to hear something substantive this fall, it sounds like. Regardless of what that outcome is, in terms of what methodology they use, do you have an idea on when the timing of that should kick in, because I guess we don’t — we only have end of one to go on. And they got three years. And it looks like your two-year anniversary of your approval at least sort of takes you already a third of the way or more into 2024 into your three. So is it — do you think it’s a good chance you’re going to have TDAPA pricings through 2024?
Chris Posner: Yes. We don’t — I’m not going to put a probability on that. But I think you got the timing right. TDAPA expires at the end of March 2024, unless we get a third year. But I think what’s also really important to point out is exactly what you pointed out is that we have been working with CMS with our partner CSL Vifor and other stakeholders around the post TDAPA funding designation and making that — working with CMS to change that appropriately to get it outside the bundle to have that an innovative product available for patients afterwards. So, we’re encouraged to where we are with CMS. But I don’t have a probability I could give you on third year, there’s there is an end of one. It’s certainly something that we would be with our partner CSL Vifor talking about at some point. But right now the focus is on working with CMS on changing the policy.
